Author/Authors :
Adimi Naghan، Parisa نويسنده Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Adimi Naghan, Parisa , Malekmohammad، Majid نويسنده , , Jamaati، Hamidreza نويسنده Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran , , Sharifkashani، Babak نويسنده Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Sharifkashani, Babak , Najafi، Arvin نويسنده Chronic Respiratory Disease Research Center, NRITLD, Shahid Beheshti University M.C., TEHRAN-IRAN. , , Hashemian، Seyed Mohammadreza نويسنده Nursing and Respiratory Health Management Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, TEHRAN-I ,
Abstract :
The objective of this study was to determine the prevalence and incidence of venous thromboembolism among critically ill medical surgical patients. In this cross sectional and retrospective study, we observed 243 patients who were first admitted at the intensive care unit. Patients who were diagnosed with deep venous thrombosis or embolism either by clinical or paraclinical methods were enrolled. Among 243 patients of ICU ward 12 cases of them were confirmed to have thromboembolism (prevalence of 9.4%).But the incidence of venous thromboembolism after 48 hour of ICU admission was 5.2%(6 cases). Among 6 VTE cases 3 of them didnʹt receive any anticoagulant prophylaxis, 2 patients received LDUH 5000 unit twice a day and one patient received LMWH 60 mg daily but all developed VTE although receiving prophylaxis. We found that the prevalence of proximal lower limb DVT among medical-surgical critically ill patients remaining in the ICU for ≥3 days is about 9.4% and the incidence of that is about 5.2%. Further studies should be performed in order to assess the benefits and risks of venous thromboprophylaxis in Iranian patients.
